Format

Send to

Choose Destination
Br J Cancer. 2013 Jan 15;108(1):163-9. doi: 10.1038/bjc.2012.540. Epub 2012 Dec 20.

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.

Author information

1
Department of Surgery and Cancer, Cancer Research UK Laboratories, Imperial College London, London, UK.

Abstract

BACKGROUND:

Endo180 (CD280; MRC2; uPARAP)-dependent collagen remodelling is dysregulated in primary tumours and bone metastasis. Here, we confirm the release and diagnostic accuracy of soluble Endo180 for diagnosing metastasis in breast cancer (BCa).

METHODS:

Endo180 was quantified in BCa cell conditioned medium and plasma from BCa patients stratified according to disease status and bisphosphonate treatment (n=88). All P-values are from two-sided tests.

RESULTS:

Endo180 is released by ectodomain shedding from the surface of MCF-7 and MDA-MB-231 BCa cell lines. Plasma Endo180 was significantly higher in recurrent/metastatic (1.71±0.87; n=59) vs early/localised (0.92±0.37; n=29) BCa (P<0.0001). True/false-positive rates for metastasis classification were: 85%/50% for the reference standard, CA 15-3 antigen (28 U ml(-1)); ≤97%/≥36% for Endo180; and ≤97%/≥32% for CA 15-3 antigen+Endo180. Bisphosphonate treatment was associated with reduced Endo180 levels in BCa patients with bone metastasis (P=0.011; n=42). True/false-positive rates in bisphosphonate-naive patients (n=57) were: 68%/45% for CA 15-3 antigen; ≤95%/≥20% for Endo180; and ≤92%/≥21% for CA 15-3 antigen+Endo180.

CONCLUSION:

Endo180 is a potential marker modulated by bisphosphonates in metastatic BCa.

PMID:
23257899
PMCID:
PMC3553530
DOI:
10.1038/bjc.2012.540
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center